Cas:857283-68-2 2-methyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-thiazole manufacturer & supplier

Chemical Name:2-methyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-thiazole

CAS.NO:857283-68-2

Synonyms:wt856

Molecular Formula:C₁₆H₂₀BNO₂S

Molecular Weight:301.21200

HS Code:2934999090

Physical and Chemical Properties:

Melting point:103ºC

Boiling point:422ºC at 760 mmHg

Density:1.14g/cm3

Index of Refraction:1.556

PSA:59.59000

Exact Mass:301.13100

LogP:3.41770

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like wt856 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,wt856 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,wt856 Use and application,wt856 technical grade,usp/ep/jp grade.

Related News: The company’s pharmaceutical intermediate business is expected to maintain a growth rate of more than 30%. 2-methyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-thiazole manufacturer The bulk-buy program, which currently covers 25 types of medicines, allows no more than three successful bidders access to China��s public hospitals, where most Chinese people buy their drugs. 2-methyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-thiazole supplier As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. 2-methyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-thiazole vendor The company’s pharmaceutical intermediate business is expected to maintain a growth rate of more than 30%. 2-methyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-thiazole factory Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview.